Similar Posts
Daiichi Sankyo Enrolls First Patient in Nimotuzumab Phase 3 Clinical Trials
ByInnokeys
Tokyo, Japan (April 25, 2013) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that the first patient has been enrolled in…
Webinar – How to Treat Locoregional Reccurent Disease of Nasopharyngeal Cancer
ByInnokeys
Speakers: 1. dr. Raymond King-Yin TSANG, MBChB, MS, FRCSEd, FRCSEd(ORL), FHKCORL, FHKAM(Otorhinolaryngology) as Head of the Division of Otorhinolaryngology of the…
New publication shows benefit in patients with locally advanced or metastatic pancreatic cancer treated with nimotuzumab
ByInnokeys
New publication shows benefit in patients with locally advanced or metastatic pancreatic cancer treated with nimotuzumab in combination with gemcitabine. The…
Patent Granted for “Treatment of Patients Diagnosed with Pancreatic Ductal Adenocarcinoma Using Monoclonal Antibodies Against the EGFR” in Russia
ByInnokeys
New patent is granted with the title of “Treatment of Patients Diagnosed with Pancreatic Ductal Adenocarcinoma Using Monoclonal Antibodies Against the EGFR”…
July 2015: Innokeys Pte Ltd Consolidates Nimotuzumab Development by Acquiring Oncoscience AG
ByInnokeys
Innokeys Pte Ltd Consolidates Nimotuzumab Development by Acquiring Oncoscience AG • The acquisition enables Innokeys to fully lead clinical and commercial development…
Webinar – Current Update on Nasopharyngeal Carcinoma
ByInnokeys
Speakers: 1. dr. Kartika Widayati, Sp.PD-KHOM from Gadjah Mada University, Indonesia 2. dr. Susanna Hilda Hutajulu, Ph.D., SpPD-KHOM from RSUP Dr. Sardjito,…